Minimum Clinically Important Difference (MCID)

MCID can be estimated for change within one person or for differences between groups. These are related but not identical. A within-person threshold asks how much one patient must improve before the change feels meaningful. A between-group threshold asks how large the average advantage of one treatment over another must be before the trial result matters in practice. Confusing those two versions can make a treatment look more or less impressive than it really is.

The study result that can be true and still feel pointless

A trial can report a “statistically significant” improvement in pain, sleep, or fatigue and still leave most people saying, “I do not feel different.” That is the exact problem MCID was built to solve. The term became widely used after Jaeschke, Singer, and Guyatt described it as the smallest difference in a health score that patients perceive as beneficial and that would justify a change in management, assuming side effects and costs are acceptable.

The surprise is this: MCID is not a magic number built into a questionnaire. It is a judgment about what size of change matters in a specific setting. A 2-point improvement may matter on one pain scale, while a 2-point improvement on another scale may be meaningless. The number depends on the tool, the condition, the starting severity, the population, and whether you are looking at one person or the average of a group.

What MCID measures

Minimum Clinically Important Difference asks a practical question: “How much does the score need to move before the change is worth caring about?” If a sleep supplement trial uses a 100-point sleep-quality score and the average score improves by 3 points, that may be statistically detectable if the study is large. But if the MCID for that scale is 8 points, the average improvement is probably too small for most users to notice.

This is why MCID is different from a p-value. A p-value asks whether the result is likely to be due to chance. MCID asks whether the size of the result has practical meaning. Both matter, but they answer different questions.

Researchers estimate MCID in two main ways. The stronger approach anchors the score change to something people can understand, such as a patient saying they feel “a little better” or “much better.” This is called an anchor-based method because the number is tied to a real-world judgment. A weaker but common approach uses the spread of scores in the dataset, such as half a standard deviation. That can help, but it does not prove patients felt better.

The supplement-reader decision

Use MCID as a filter before you trust a headline. If a supplement study reports a significant improvement on a symptom questionnaire, look for the actual size of the change and compare it with the MCID for that exact scale. If the change is below the MCID, the honest takeaway is not “it works.” The better takeaway is: “The study detected a small movement, but it may be below the level most people would feel.”

Regulators care about this distinction too. The U.S. Food and Drug Administration guidance on patient-reported outcome measures says trial results should support claims of treatment benefit, not merely show movement on a questionnaire. In plain terms, a score change needs a human meaning before it becomes a convincing benefit claim.

A common failure mode is comparing a study’s result with an MCID from a different scale. A 3-point change on one pain questionnaire cannot be judged using the MCID from another pain questionnaire. Match the scale name, score range, condition, and population before deciding whether the result matters.